Numerion Labs
Numerion Labs applies artificial intelligence to discover and optimize small-molecule drug candidates faster than traditional screening. It uses the AtomNet platform—convolutional neural networks trained on large chemical libraries combined with high-performance compute—to perform structure-based drug discovery. The company operates as a B2B drug discovery partner to pharmaceutical, agrochemical, and biotechnology firms while advancing a pipeline of wholly owned and co-developed preclinical assets. Its platform has been applied across hundreds of disease targets through large-scale computational screens and industry partnerships.
Numerion Labs
Numerion Labs applies artificial intelligence to discover and optimize small-molecule drug candidates faster than traditional screening. It uses the AtomNet platform—convolutional neural networks trained on large chemical libraries combined with high-performance compute—to perform structure-based drug discovery. The company operates as a B2B drug discovery partner to pharmaceutical, agrochemical, and biotechnology firms while advancing a pipeline of wholly owned and co-developed preclinical assets. Its platform has been applied across hundreds of disease targets through large-scale computational screens and industry partnerships.